exclud fx result ahead expect
revenu growth exceed forecast thank lower tax rate
control spend adj ep growth despit stronger fx headwind
beyond result perceiv mgmt tone especi confid
upbeat recal ever earn call confid clearli drove
share intra-day call commentari bullish mani area
convict express libr approv reimburs mitraclip
confirm success plan place address investor concern around
leadership plan overal set bullish tone remaind year
isnt one materi catalyst propel multipl forward libr
mitraclip momentum turnaround challeng busi eas comp
back half drive reliabl strong result near-term see littl risk
execut share trade next twelv month ep
estim share valuat seem appropri reflect mani posit
share may advanc continu bull market co like keep
deliv strong result see well-abov histor multipl offer
risk anyth throughout world chang cours futur thu
reiter neutral rate
grew robust rate libr improv beat
street anecdot commentari libr user payor uptak wasnt
entir new manag optim libr differenti mass market
appeal improv margin profil appear posit usual
talk hit sale mayb even certainli propel share
ceo would commit upsiz market management believ
potenti expand product applic beyond glucos like nearer
term expect momentum driven upcom libr approv
co expect rel soon improv demand fulfil
mitraclip potenti far unclip mitraclip growth
impress heel fda approv fmr growth support
improv penetr exist account clinical/field sale expans
notabl eu result rebound seem doc focus coapt
mitra-fr go forward franchis benefit expans
japan reimburs expect end earli
valuat maintain neutral rate risk page
idc btig estim compani document
million except per share amount
abbott rate neutral abbott benefit solid pipelin launch high-growth area
diabet diagnost remain posit abt base busi see pathway drive high singl digit
growth although mitraclip still modest portion busi expect signific ramp
follow label expans fmr said share trade high-teen premium comp group
feel share rel valuat appropri reflect risk vs reward
abbott one largest
nutrit diagnost
stabl procedur growth price
expans current tam
cut reimburs
report revenu slightli street-high forecast sizabl fx headwind skew
report result posit constant currenc growth vs forecast
devic segment revenu slightli weaker street estim weaker neuromod ep result diabet revenu
modestli consensu forecast howev libr sale exceed street
estim sequenti libr sale grew libr perform continu bolster favor payor
trend strong demand back impress real-world data turn mitraclip sale growth
eu revenu improv doubl digit neuromod revenu fell short consensu forecast
compani anticip improv newli hire salesforc turn product recent increas
headcount
turn diagnost organ sale growth alin growth continu stellar europ molecular
diagnost weak quarter declin organ due volatil purchas pattern africa dont
see long-term neg previous indic pend fda approv compani hope roll
broader test menu alin platform acceler growth back half
report basi establish pharma perform in-lin sale key emerg market includ india brazil
russia china grew organ basi
lastli organ nutrit sale growth slightli ahead model perform broad-bas strong
growth seen asia latin america
gross margin forecast sg spend wors model offset
 came better estim tax rate estim help
deliv beat vs forecast
actualsbtig estimate variancetot incom net bpssg spend bpsr spend bpsebit bpstax bpssourc btig estim compani filingsvari
make modest chang overal revenu forecast though increas diagnost estim slightli
better outlook model constant currenc revenu growth littl chang vs previou
estim turn oper margin taken full-year gross margin assumpt account
manufactur invest back half improv estim net-net adj ebit margin remain
unchang line reduc tax rate match compani outlook aggreg
adj ep estim move
abbott rate neutral share all-tim high benefit solid pipelin launch high-growth
area diabet diagnost remain posit base busi see pathway toward
drive high-single-digit revenu growth although mitraclip still modest portion busi expect signific
ramp label expans potenti reimburs said share trade high-teen premium
comp group histor averag feel share rel valuat appropri reflect risk vs reward btig
provid price target neutral-r stock risk includ multipl expans competit healthcar polici chang
healthcar fall favor fda regulatori agenc product delay
exhibit comp tabl large-cap peer
 net ep gross bpsnmadj ebit bpsnm btig estim compani filingsnewold changecagrntm johnsonjnjnot fishertmobuy bdxnot scientificbsxbuy factset data btig estimatesintra-day price ex-amortcompanytickerr ptpricemarket cap
abbott incom statement sale ex oper interest incom incom tax expens net ep methodology/abt share net incom ep incl disc marginsgross expensescog oper expens ep btig estim compani report
abbott segment y/i y/i y/i y/i y/i medic devic report pre-acqestablish pharmaceuticalkey emerg market y/i growth y/i y/i growth y/i growth y/i y/i growth y/i growth y/i y/i growth y/i growth y/i y/i growth y/i growth btig estim compani report
abbott segment laboratori y/i laboratori y/i growth laboratori y/i growth y/i y/i growth y/i growth y/i y/i growth y/i growth diagnost y/i diagnost y/i growth diagnost y/i growth oper adj y/i y/i growth y/i growth oper adj btig estim compani report
abbott segment devicesrhythm manag y/i manag y/i growth manag y/i growth y/i y/i growth y/i growth failur y/i failur y/i growth failur y/i growth y/i y/i growth y/i growth heart y/i heart y/i growth heart y/i growth y/i y/i growth y/i growth y/i y/i growth y/i growth devic y/i devic y/i growth devic y/i growth totaltot report segment us y/i report segment y/i report segment ww y/i btig estim compani adjust stj acquisit optic divestitur
btig cover compani mention report
appendix analyst certif import disclosur
